| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 36.9 | 25.2 | 22.4 |
| Total income | 36.9 | 25.2 | 22.4 |
| Profit before exceptional items & tax | 1.1 | 1.2 | 0.2 |
| Profit before tax | 1.1 | 1.2 | 0.2 |
| Net profit | 1.2 | 0.9 | 0.1 |
| Operating margin | 3.0% | 4.8% | 0.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +1100.00% |
|---|---|
| Net profit, quarter on quarter | +33.30% |
| Revenue, year on year | +64.70% |
Source
Read the filing ↗
BSE results filing, NSE: TRIMURTHI. Figures extracted from the filing.
Novelix Pharmaceuticals Ltd: key numbers
- Share price
- ₹70.38
- Market cap
- ₹124.0 Cr
- Revenue (annual)
- ₹132.3 Cr
- Net profit (annual)
- ₹2.56 Cr
- P/E (TTM)
- 34.2×Sector 67.6×
- Promoter holding
- 54.29%+4.86% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novelix Pharmaceuticals Ltd
All →
22:22 IST
BSE
Other Announcement
Novelix Pharmaceuticals Other Announcement
Novelix Pharmaceuticals informs shareholders that the Annual Report for FY 2025-26 and the 32nd AGM notice are available on the Company's website.
22:16 IST
BSE
Annual Report
Novelix Pharmaceuticals Annual Report
Novelix Pharmaceuticals filed its Annual Report and AGM Notice for the financial year 2025-26. The 32nd Annual General Meeting is scheduled for September 30, 2026.